Mesoblast reports Ryoncil revenue surge and improved cash spend
AI Market Summary
Mesoblast's Q1 update shows Ryoncil revenue up 44% to US$28m and operating cash burn cut 85% to US$2.3m, with US$99m cash at 30 September 2026. The improvements reflect wider adoption across 54 sites and tighter capital discipline, easing near-term funding risk for the ASX-listed biotech. Impact is company-specific, with little read-through to broader indices or sector sentiment.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.66%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Mesoblast shares in focus after Q1 results show Ryoncil revenue up 44% and major cash spend improvement. Find out what's next for the ASX biotech.
